Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 382.1% in January

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,615 shares, an increase of 382.1% from the January 15th total of 335 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 19,331 shares, the short-interest ratio is presently 0.1 days. Based on an average daily volume of 19,331 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Alterity Therapeutics Stock Down 1.7%

Shares of NASDAQ ATHE opened at $3.47 on Friday. Alterity Therapeutics has a 1-year low of $2.52 and a 1-year high of $7.00. The company has a 50-day moving average of $3.27 and a two-hundred day moving average of $4.07.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ATHE. Canaccord Genuity Group began coverage on Alterity Therapeutics in a report on Wednesday, December 17th. They issued a “speculative buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Alterity Therapeutics currently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Greenleaf Trust increased its stake in shares of Alterity Therapeutics by 88.2% in the 3rd quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after buying an additional 15,000 shares during the period. Citadel Advisors LLC bought a new position in Alterity Therapeutics in the third quarter valued at about $83,000. HB Wealth Management LLC acquired a new stake in Alterity Therapeutics in the third quarter worth about $220,000. Finally, Twin Lakes Capital Management LLC raised its holdings in Alterity Therapeutics by 2,250.3% during the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock worth $524,000 after purchasing an additional 133,333 shares during the last quarter. Institutional investors and hedge funds own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.